Agent Company Indication Targets References
Sorafenib Onyx/Bayer RCC, HCC VEGFR, PDGFR, c-Kit, Raf [38-41]
Nilotinib Novartis CML Bcr-Abl, PDGFR, cSrc, c-Kit [42]
Sunitinib Pfizer GIST, RCC PDGFR, VEGFR, c-Kit, RET, FLT3 [43]
Crizotinib Pfizer NSCLC EML4/ALK, HGFR [44, 45,223]
Motesanib Amgen/Takeda Breast cancer PDGFR, VEGFR, c-Kit [46]
Vandetanib Astra Zeneca Thyroid, NSCLC EGFR, VEGFR, RET [30]
Lesaurtinib Cephalon AML JAK2, FLT3, Trk [48,49]
Cabozatinib Exelixis Thyroid, solid tumors VEGFR, MET, c-Kit, FLT3, RET, TEK [51,52]
Pazopanib GlaxoSmithKline RCC, sarcoma VEGFR, PDGFR, c-Kit [53]
Abbreviations: RCC: Renal cell carcinoma; HCC: Hepato cellular carcinoma; CML: Chronic myelogenousleukemia; GIST: Gastro-intestinal stromal tumor; NSCLC: Nonsmall- cell Lung cancer; AML: Angiomyolipoma; VEGFR: Vascular endothelial growth factor receptor; PDGFR: Platelet-derived growth factor receptor; cKit: Mast/stem cell growth factor receptor; cSrc: tyrosine-protein kinase; Bcr-Abl: Break cluster region-Abelson leukemia; RET: REarranged during transfection; FLT3: FMS-like tyrosine kinase 3; EML4: Echinoderm microtubule-associated protein-like 4; ALK: Anaplastic lymphoma kinase; HGFR: Hepatocyte growth factor receptor; JAK2: Janus kinase 2; Trk: Tropomyosinreceptorkinase; TEK: Tyrosine kinase, endothelial.
Table 1: Single-agent MTIs currently undergoing preclinical and clinical use.